squibb
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.
Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer
Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy
Bristol Myers Terminates Partnership with Immatics on Bispecific Cancer Drug After $150M Investment
Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Biopharma Layoff Tracker 2024: Precigen, Sumitomo, BMS and More Cut Staff
biopharma layoffs, Precigen, Sumitomo, Bristol Myers Squibb, biotech industry, job cuts, restructuring, pharmaceutical companies
Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus
Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions